Intact monoclonal antibodies separation and analysis by sheathless capillary electrophoresis-mass spectrometry

Eur J Mass Spectrom (Chichester). 2019 Jun;25(3):324-332. doi: 10.1177/1469066718807798. Epub 2018 Oct 23.

Abstract

Capillary electrophoresis-mass spectrometry coupling is a growing technique in biopharmaceutics characterization. Assessment of monoclonal antibodies is well known at middle-up and bottom-up levels to obtain information about the sequence, post-translational modifications and degradation products. Intact protein analysis is an actual challenge to be closer to the real protein structure. At this level, actual techniques are time consuming or cumbersome processes. In this work, a 20 minutes separation method has been developed to optimize characterization of intact monoclonal antibodies. Thus, separation has been done on a positively charged coated capillary with optimized volatile background electrolyte and sample buffer. Three world-wide health authorities approved monoclonal antibodies have been used to set up a rapid and ease of use method. Intact trastuzumab, rituximab and palivizumab isoforms have been partially separated with this method in less than 20 minutes under denaturing conditions. For each monoclonal antibody, 2X-glycosylated and 1X-glycosylated structures have been identified and separated. Concerning basic and acidic variants, potential aspartic acid isomerization modification and asparagine deamidation have been observed. Accurate mass determination for high-mass molecular species remains a challenge, but the progress in intact monoclonal antibodies separation appears very promising for biopharmaceutics characterization.

Keywords: Capillary electrophoresis; glycoform separation; mass spectrometry; micro-variant separation; monoclonal antibody.

Publication types

  • Evaluation Study

MeSH terms

  • Electrophoresis, Capillary / methods*
  • Glycosylation
  • Isomerism
  • Mass Spectrometry / methods*
  • Protein Processing, Post-Translational
  • Trastuzumab / chemistry*
  • Trastuzumab / isolation & purification

Substances

  • Trastuzumab